1. Introduction {#sec1-ijerph-17-00171}
===============

Human immunodeficiency virus (HIV) continues to be a serious threat to the health of Hispanic/Latino communities. Hispanics/Latinos represented 18% of the US population in 2015 but accounted for 27% of new HIV diagnoses in 2016 \[[@B1-ijerph-17-00171]\]. Despite overall improvements in HIV outcomes in the United States, disparities still exist between Hispanic and non-Hispanic persons with diagnosed HIV. A lower proportion of Hispanics/Latinos than non-Hispanic whites with diagnosed HIV received HIV medical care and had suppressed viral load \[[@B2-ijerph-17-00171]\]. Viral suppression is dependent on timely diagnosis and linkage to and retention in HIV medical care. Overall, Hispanics/Latinos with diagnosed HIV were more likely to enter HIV care late in the disease course, often with a concurrent acquired immunodeficiency syndrome (AIDS) diagnosis, and less likely to be linked to medical care compared with non-Hispanic whites \[[@B3-ijerph-17-00171],[@B4-ijerph-17-00171]\]. Improving access to care, retention in care, and viral suppression among Hispanic/Latino populations with diagnosed HIV is needed to reduce disparities and achieve national prevention goals \[[@B5-ijerph-17-00171]\].

Hispanics/Latinos born outside of the mainland United States comprised 61% of Hispanics/Latinos with diagnosed HIV in the United States in 2003--2006 \[[@B6-ijerph-17-00171]\]. Of people who received a diagnosis of HIV in the United States in 2007--2010, 42% of Hispanics/Latinos were born outside of the United States and its territories, compared with only 3% of non-Hispanic whites and 10% of non-Hispanic blacks born outside of the United States and its territories \[[@B7-ijerph-17-00171]\]. Analyses that do not stratify estimates for Hispanics/Latinos by place of birth cannot identify similarities and differences in important health outcomes and associated factors within the Hispanic/Latino community.

Non-US-born persons with diagnosed HIV were more likely to be prescribed antiretroviral therapy (ART), retained in care, and virally suppressed, compared with US-born persons \[[@B8-ijerph-17-00171]\]. However, national estimates that describe HIV care outcomes among Hispanics/Latinos by place of birth are limited \[[@B4-ijerph-17-00171]\]. A preliminary analysis that categorized Hispanics/Latinos born in Puerto Rico (PR) with the US-born group demonstrated no significant differences in HIV care outcomes. As a result, we analyzed more recent data to describe social determinants of health, behavioral characteristics, and HIV care outcomes by place of birth among Hispanic/Latino adults with diagnosed HIV, treating the PR-born Hispanics/Latinos as a separate group. Comparing characteristics, including HIV care outcomes, between mainland-US-born, PR-born, and non-US-born Hispanics/Latinos at the national level, can inform tailored HIV prevention and treatment efforts to end the HIV epidemic in Hispanic/Latino communities.

2. Materials and Methods {#sec2-ijerph-17-00171}
========================

The Medical Monitoring Project (MMP) is an annual cross-sectional survey designed to produce nationally representative estimates of behavioral and clinical characteristics of adults with diagnosed HIV in the United States. MMP data collection is a part of routine public health surveillance, and thus, determined to be nonresearch \[[@B9-ijerph-17-00171]\]. Participating areas obtained local institutional review board approval to collect data when required. All participants provided informed consent.

2.1. Sampling {#sec2dot1-ijerph-17-00171}
-------------

MMP uses a two-stage sampling method in which, during the first stage, 23 project areas were sampled from all US states, the District of Columbia, and Puerto Rico \[[@B10-ijerph-17-00171]\]. During the second stage, simple random samples of persons with diagnosed HIV aged 18 years and older were drawn for each jurisdiction from the National HIV Surveillance System (NHSS), a census of persons with diagnosed HIV in the United States.

All sampled states and Puerto Rico participated in MMP. Participating areas included California, Delaware, Florida, Georgia, Illinois, Indiana, Michigan, Mississippi, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Puerto Rico, Texas, Virginia, and Washington. Separately funded cities or jurisdictions include Los Angeles County, San Francisco, Chicago, New York City, Philadelphia, and Houston. For this analysis, we combined three cycle years of MMP data: 2015, 2016, and 2017. Data collection began on June 1 of the cycle year and ended on May 31 of the following calendar year. For each cycle, the sampling frame was adults with diagnosed HIV reported to NHSS as of December 31 of the prior year. The response rate for adults with diagnosed HIV was 40%, 44%, and 46% for the 2015, 2016, and 2017 MMP cycles, respectively. Data were weighted on the basis of known probabilities of selection at state or territory and person levels \[[@B11-ijerph-17-00171]\]. Further, data were weighted to adjust for person nonresponse and post-stratified to NHSS population totals by sex, race/ethnicity, and age \[[@B12-ijerph-17-00171]\].

2.2. Data Collection and Classification {#sec2dot2-ijerph-17-00171}
---------------------------------------

Data were collected via telephone or face-to-face interviews and medical record abstractions from June 2015 to May 2018. Interviews were conducted in English or Spanish. All measures were assessed over the 12 months before the date of the interview unless otherwise noted. Medical records were abstracted at the health care facility the participant identified as their most frequent source of HIV care. Abstracted information included documented prescription of ART, laboratory results, and health care use. Persons born in the mainland US (50 States and Washington DC) were classified as *mainland*-*US-born*, those born in Puerto Rico were classified as *PR-born,* and those born elsewhere were classified as *non-US-born*. Hispanics/Latinos born in US territories other than Puerto Rico were excluded from this analysis due to small cell size. We also categorized PR-born Hispanics/Latinos as currently residing in Puerto Rico or the US mainland.

2.3. Sociodemographic and Behavioral Characteristics {#sec2dot3-ijerph-17-00171}
----------------------------------------------------

For non-US-born Hispanics/Latinos, age at the time of immigration to the United States was categorized as younger than 18 years old and 18 years or older. The date of diagnosis relative to immigration was calculated by comparing the reported date the person immigrated to the United States with their first HIV diagnosis date. Transgender Hispanics/Latinos were not included in the gender category because of small cell sizes. Binge drinking was defined as drinking five or more alcoholic beverages in a single sitting for men and four or more alcoholic beverages in a single sitting for women in the 30 days prior to the interview. Depression in the past two weeks was assessed using the eight-item Patient Health Questionnaire Depression Scale (PHQ-8) \[[@B13-ijerph-17-00171]\], and anxiety in the past two weeks was assessed using the Generalized Anxiety Disorder Scale (GAD-7) \[[@B14-ijerph-17-00171]\]. Scales for depression and anxiety were categorized based on clinically meaningful cut points, and detailed algorithms are reported elsewhere \[[@B10-ijerph-17-00171]\].

2.4. HIV Care and Clinical Outcome Measures {#sec2dot4-ijerph-17-00171}
-------------------------------------------

Documentation in the medical record of ART prescription in the 12 months before interview was assessed. Retention in care was defined as documentation of two elements of outpatient HIV care at least 90 days apart in the past 12 months. Outpatient HIV care was defined as documentation in the medical record of any of the following: an encounter with an HIV care provider (could also be self-reported), viral load test result, CD4 test result, HIV resistance test or tropism assay, ART prescription, *Pneumocystis jiroveci* pneumonia prophylaxis, or *Mycobacterium avium* complex prophylaxis. Viral suppression was defined as an HIV RNA level that was undetectable or \< 200 copies/mL. Recent viral suppression was defined as virally suppressed at the most recent test, and sustained viral suppression was defined as virally suppressed at all tests in the past 12 months. Adherence to ART doses was assessed using a 3-item scale \[[@B15-ijerph-17-00171]\]. Participants were asked how many days they missed at least one dose of their HIV medicines, how often they took their HIV medicines in the way they were supposed to, and how good a job they did at taking their HIV medicines in the way they were supposed to during the 30 days before the interview. Among persons who are taking ART, those who reported no missed doses, always took HIV medicines, and felt they did an excellent job at taking HIV medicines in the way they were supposed to were considered 100% adherent to ART doses.

2.5. Analysis {#sec2dot5-ijerph-17-00171}
-------------

The analytic dataset included 2564 adults with diagnosed HIV that self-identified as Hispanic/Latino, including 944 born in the United States mainland, 634 born in Puerto Rico (of whom 435 currently reside in Puerto Rico and 199 reside in the mainland United States), and 986 born outside the United States. We calculated weighted prevalences with 95% confidence intervals (CI) for demographic, behavioral, and clinical characteristics. Estimates with coefficients of variation ≥0.3 were considered unreliable and were not reported.

For the analysis, we first reported characteristics of Hispanic/Latino adults with diagnosed HIV by place of birth. Next, we examined differences in selected characteristics and HIV care outcomes by place of birth. We used logistic regression with predicted marginal means to estimate unadjusted prevalence ratios and corresponding 95% CIs using the mainland-US-born as the reference group. Finally, we assessed differences in HIV clinical outcomes by place of residence among PR-born persons using Rao--Scott chi-square tests. For all analyses, associations with a *p*-value of \< 0.05 were considered statistically significant.

3. Results {#sec3-ijerph-17-00171}
==========

3.1. Sociodemographic, Behavioral and Clinical Characteristics {#sec3dot1-ijerph-17-00171}
--------------------------------------------------------------

Among Hispanic/Latino adults with diagnosed HIV, an estimated 40% were born in the mainland United States, 22% were born in Puerto Rico, and 38% were born outside of the United States ([Table 1](#ijerph-17-00171-t001){ref-type="table"}). Most Hispanics/Latinos with diagnosed HIV were men, regardless of place of birth. Among the PR-born, 67% currently reside in Puerto Rico. Among non-US-born Hispanics/Latinos, nearly half (49%) were born in Mexico. Over three-quarters of non-US-born Hispanics/Latinos immigrated to the United States at age 18 years or older, and most had lived in the United States for 10 or more years. Among non-US-born Hispanics/Latinos, 10% received an HIV diagnosis at least one year before relocating to the United States, 5% received an HIV diagnosis the same year as their arrival, and more than half received an HIV diagnosis 10 or more years after immigrating to the United States.

A lower proportion of PR-born compared with mainland-US-born and non-US-born Hispanics/Latinos were men ([Table 2](#ijerph-17-00171-t002){ref-type="table"}). PR-born and non-US-born Hispanics/Latinos were older and were less likely to complete a high school diploma or equivalent education than mainland-US-born Hispanics/Latinos. PR-born or non-US-born Hispanics/Latinos were more likely to live in a household at or below the federal poverty level and receive care at a Ryan White HIV/AIDS Program (RWHAP)-funded facility compared with mainland-US-born Hispanics/Latinos. There was a significantly higher proportion of non-US-born Hispanics/Latinos who had any RWHAP coverage in the past 12 months compared with mainland-US-born.

Non-US-born Hispanics/Latinos were less likely to binge drink, use non-injection drugs, and report symptoms of depression and anxiety compared with mainland-US-born Hispanics/Latinos ([Table 2](#ijerph-17-00171-t002){ref-type="table"}). PR-born Hispanics/Latinos were less likely to use non-injection and injection drugs compared with mainland-US-born Hispanics/Latinos. PR-born and non-US-born Hispanics/Latinos were more likely to have an AIDS diagnosis compared with mainland-US-born Hispanics/Latinos.

3.2. HIV Outcomes {#sec3dot2-ijerph-17-00171}
-----------------

PR-born Hispanics/Latinos were more likely to have been prescribed ART (94%), retained in care (94%), and virally suppressed at their most recent viral load test (85%) compared with mainland-US-born (79%, 77%, and 65%, respectively) Hispanics/Latinos ([Table 3](#ijerph-17-00171-t003){ref-type="table"}). Non-US-born Hispanics/Latinos were more likely to have been prescribed ART (91%), retained in care (87%), and virally suppressed at their most recent viral load test (80%) compared with mainland-US-born (79%, 77%, and 65%, respectively) Hispanics/Latinos. A higher proportion of PR-born (75%) and non-US-born (74%) Hispanics/Latinos compared with 57% of mainland-US-born Hispanics/Latinos had sustained viral suppression.

PR-born Hispanics/Latinos who resided in Puerto Rico were more likely to have been prescribed ART (96%), been retained in care (97%), and had sustained viral suppression (78%) compared with those who resided in the US mainland at the time of sampling (91%, 88%, and 68% respectively) ([Table 4](#ijerph-17-00171-t004){ref-type="table"}).

4. Discussion {#sec4-ijerph-17-00171}
=============

Our findings demonstrate disparities in HIV care outcomes among Hispanics/Latinos with diagnosed HIV by place of birth. Although Hispanics/Latinos born outside of the mainland US had a higher prevalence of AIDS, they were more likely to be on ART, be engaged in care, and virally suppressed compared with mainland-US-born Hispanics/Latinos. Similarly, previous studies reported a higher proportion of non-US-born blacks compared with US-born blacks were retained in HIV medical care and virally suppressed \[[@B16-ijerph-17-00171]\]. Sheena and colleagues also reported a higher prevalence of linkage to HIV care after diagnosis among PR-born Hispanics/Latinos residing in Florida, compared with their mainland-US-born counterparts \[[@B17-ijerph-17-00171]\].

One possible explanation for these outcome disparities may be that more advanced disease among PR-born and non-US-born groups may have resulted in closer medical follow-up that may have led to better HIV care outcomes, such as retention in care. Similarly, a study of patients at two academic medical centers in Massachusetts found that non-US-born persons with HIV more often presented with late-stage disease but were more likely to be linked to care compared with US-born counterparts \[[@B18-ijerph-17-00171]\].

Another possible reason for poorer HIV outcomes among Hispanics/Latinos born in the US mainland may be differences in the utilization of RWHAP and receipt of care at RWHAP-funded facilities. A lower percentage of mainland-US-born than PR-born and non-US born Hispanics/Latinos received care at RWHAP- funded facilities, which may have contributed to the disparity in HIV care outcomes observed by place of birth. The RWHAP provides funds to HIV clinics to increase access to high-quality HIV care and treatment, including financial assistance for HIV medications and access to supportive services for low-income, uninsured, and underinsured individuals and families affected by HIV \[[@B19-ijerph-17-00171]\]. The RWHAP functions as a safety net provider of HIV care and treatment for people who are unable to obtain other forms of health care coverage. Receipt of care at RWHAP-funded facilities has consistently been associated with higher levels of viral suppression among low-income persons \[[@B5-ijerph-17-00171],[@B20-ijerph-17-00171],[@B21-ijerph-17-00171]\].

Differences in mental health and substance use are another possible explanation for HIV outcome disparities found between the examined groups. Mainland-US-born Hispanics/Latinos were more likely than PR-born and non-US-born Hispanics/Latinos to report the use of drugs and were more likely than non-US-born Hispanics/Latinos to report symptoms of anxiety and depression. Psychiatric illnesses combined with substance use are associated with poor HIV outcomes \[[@B22-ijerph-17-00171],[@B23-ijerph-17-00171]\]. Persons with diagnosed HIV who are using drugs are less likely to adhere to treatment and achieve viral suppression \[[@B22-ijerph-17-00171]\], and those who are experiencing current symptoms of depression combined with the use of cocaine or methamphetamine were found to have lower odds of virologic suppression \[[@B23-ijerph-17-00171]\].

We further stratified PR-born Hispanics/Latinos with diagnosed HIV by their current residence and found that PR-born Hispanic/Latinos who resided in Puerto Rico were more likely to be prescribed ART, retained in care, and sustainably virally suppressed compared with those who resided in the mainland US. PR-born Hispanics/Latinos who live on the island were the only groups that reached the national HIV prevention goal of 90% retention in care among persons with HIV \[[@B17-ijerph-17-00171]\]. Availability and accessibility of HIV services on the island may be one factor that contributed to favorable outcomes among PR-born Hispanics/Latinos residing on the island. One study found that Puerto Rican adults had better access to health care, after controlling for sociodemographic factors, including income, compared with their counterparts on the US mainland \[[@B24-ijerph-17-00171]\]. The difference in HIV care outcomes between PR-born Hispanics/Latinos who reside on the island and in the US mainland needs further research because the migration of Puerto Ricans to the mainland US has accelerated in recent years \[[@B25-ijerph-17-00171]\]. Puerto Ricans who relocate to the mainland US may experience interruptions accessing and staying in HIV care.

Our analysis is subject to limitations. First, MMP's design is cross-sectional, and thus, causal relationships between sociodemographic, behavioral, and clinical characteristics and HIV outcomes cannot be inferred. Second, MMP's person-level response rate was low; however, the data were adjusted for nonresponse, which should reduce bias. Third, medical records were abstracted from the facility where the person received the most HIV care, not from all facilities that provided care. Thus, our findings may not be inclusive of all possible medical services the person received.

5. Conclusions {#sec5-ijerph-17-00171}
==============

Disparities in HIV care outcomes exist among Hispanics/Latinos with diagnosed HIV by place of birth. Factors contributing to favorable HIV care outcomes may include the utilization of RWHAP-funded facilities among PR-born persons and better mental health and less drug use among non-US-born persons. Expanding access and reducing barriers to the use of comprehensive HIV/AIDS programs that provide care to the whole person, including treating mental health and substance use issues, may reduce HIV care outcome disparities and support ending the HIV epidemic in Hispanic/Latino communities.
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###### 

Hispanic/Latino adults with diagnosed HIV by place of birth, United States---Medical Monitoring Project, 2015--2018 (n = 2564).

  Characteristics                                                            Mainland-US-Born   Puerto Rico-Born    Non-US-Born                             
  -------------------------------------------------------------------------- ------------------ ------------------- ------------- ------------------- ----- -------------------
  **Total**                                                                  944                39.8 (33.2--46.4)   634           21.9 (8.8--35.0)    986   38.3 (31.0--45.5)
  **Currently reside in Puerto Rico**                                        \-                 \-                  435           66.6 (40.6--92.7)   \-    \-
  **Gender**                                                                                                                                                
   Male                                                                      721                80.9 (78.0--83.7)   411           70.6 (66.6--74.6)   776   81.8 (79.0--84.7)
   Female                                                                    205                19.1 (16.3--22.0)   212           29.4 (25.4--33.4)   185   18.2 (15.3--21.0)
  **Age (Years)**                                                                                                                                           
   18--34                                                                    254                27.0 (23.5--30.5)   51            7.2 (5.1--9.2)      131   13.1 (10.4--15.7)
   35--44                                                                    181                21.9 (18.4--25.5)   96            16.0 (12.9--19.1)   265   28.2 (24.7--31.7)
   45--54                                                                    283                28.7 (25.2--32.3)   229           37.5 (34.4--40.6)   366   36.5 (33.2--39.9)
   ≥55                                                                       226                22.4 (19.2--25.5)   258           39.3 (35.1--43.4)   224   22.2 (19.1--25.3)
  **Education**                                                                                                                                             
   \<High school                                                             181                16.8 (14.1--19.5)   184           29.2 (25.0--33.3)   341   35.2 (31.9--38.6)
   High school diploma or equivalent                                         244                25.4 (21.9--28.8)   164           26.8 (22.3--31.3)   225   22.8 (19.9--25.7)
   \>High school                                                             518                57.8 (53.7--61.9)   285           44.0 (39.5--48.5)   415   42.0 (38.1--45.9)
  **At or below federal poverty level**                                      373                39.7 (35.8--43.6)   412           66.2 (62.0--70.4)   448   47.9 (44.1--51.8)
  **Speaks language other than English at home**                             532                56.3 (52.0--60.6)   607           96.6 (93.8--99.4)   875   88.9 (86.2--91.6)
  **Speaks English well or very well**                                       924                98.1 (97.0--99.2)   334           53.2 (40.8--65.6)   628   64.2 (60.2--67.9)
  **Received care at a Ryan White HIV/AIDS Program-funded facility ^a,b^**   631                68.9 (64.5--73.4)   584           91.0 (83.6--98.5)   742   77.8 (73.4--82.3)
  **Had any Ryan White coverage ^c^**                                        402                40.4 (36.2--44.7)   257           43.7 (37.1--50.3)   603   62.9 (58.9--66.9)
  **Country of birth**                                                                                                                                      
   Caribbean                                                                 \-                 \-                  \-            \-                  153   15.4 (12.1--18.7)
   Central America                                                           \-                 \-                  \-            \-                  177   17.1 (14.2--20.0)
   Mexico                                                                    \-                 \-                  \-            \-                  474   48.6 (43.6--53.6)
   South America                                                             \-                 \-                  \-            \-                  157   16.2 (13.2--19.2)
   Others                                                                    \-                 \-                  \-            \-                  24    2.7 (1.3--4.0)
  **Age at migration (Years)**                                                                                                                              
   \<18                                                                      \-                 \-                  \-            \-                  231   24.2 (21.1--27.4)
   ≥18                                                                       \-                 \-                  \-            \-                  750   75.8 (72.6--78.9)
  **Time living in the United States (Years)**                                                                                                              
   \<5                                                                       \-                 \-                  \-            \-                  44    5.1 (3.2--6.9)
   5--9                                                                      \-                 \-                  \-            \-                  51    4.2 (3.0--5.5)
   ≥10                                                                       \-                 \-                  \-            \-                  886   90.7 (88.6--92.8)
  **Date of diagnosis relative to immigration**                                                                                                             
   ≥5 years before arrival                                                   \-                 \-                  \-            \-                  51    5.1 (3.5--6.6)
   1--4 years before arrival                                                 \-                 \-                  \-            \-                  44    4.7 (3.1--6.3)
   Same year as arrival                                                      \-                 \-                  \-            \-                  42    5.0 (3.4--6.7)
   1--4 years after arrival                                                  \-                 \-                  \-            \-                  136   13.7 (11.3--16.1)
   5--9 years after arrival                                                  \-                 \-                  \-            \-                  191   19.0 (16.1--21.8)
   ≥10 years after arrival                                                   \-                 \-                  \-            \-                  516   52.5 (49.0--56.1)

Notes: CI, Confidence Interval; all percentages are weighted; time period is 12 months prior to interview unless otherwise noted; all measures are self-reported unless otherwise noted. ^a^ Any Parts A, B, C, D, or F funding. ^b^ Documented in medical record. ^c^ Includes AIDS Drug Assistance Program (ADAP) and other RWHAP support.
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###### 

Comparison of selected demographic, behavioral, and clinical characteristics of Hispanic/Latino adults with diagnosed HIV by place of birth, United States--- Medical Monitoring Project, 2015--2018 (n = 2564).

                                                                             Weighted Row % (95% CI)   Prevalence Ratio (95% CI)   *p*-Value ^a^
  -------------------------------------------------------------------------- ------------------------- --------------------------- ---------------
  **Gender (Male)**                                                                                                                
   Mainland-US-born                                                          80.9 (78.0--83.7)         Ref.                        \--
   Puerto Rico-born                                                          70.6 (66.6--74.6)         0.87 (0.82--0.93)           \<0.0001
   Non-US-born                                                               81.8 (79.0--84.7)         1.01 (0.96--1.06)           0.641
  **Age (18--44 Years)**                                                                                                           
   Mainland-US-born                                                          48.9 (44.9--53.0)         Ref.                        \-
   Puerto Rico-born                                                          23.2 (19.8--26.6)         0.47 (0.40--0.56)           \<0.0001
   Non-US-born                                                               41.3 (37.5--45.0)         0.84 (0.75--0.95)           0.0064
  **Education (\<High school)**                                                                                                    
   Mainland-US-born                                                          16.8 (14.1--19.5)         Ref.                        \-
   Puerto Rico-born                                                          29.2 (25.0--33.3)         1.74 (1.41--2.14)           \<0.0001
   Non-US-born                                                               35.2 (31.9--38.6)         2.10 (1.74--2.53)           \<0.0001
  **At or below federal poverty level**                                                                                            
   Mainland-US-born                                                          39.7 (35.8--43.6)         Ref.                        \-
   Puerto Rico-born                                                          66.2 (62.0--70.4)         1.67 (1.49--1.87)           \<0.0001
   Non-US-born                                                               47.9 (44.1--51.8)         1.21 (1.07--1.36)           0.0022
  **Speaks language other than English at home**                                                                                   
   Mainland-US-born                                                          56.3 (52.0--60.6)         Ref.                        \-
   Puerto Rico-born                                                          96.6 (93.8--99.4)         1.72 (1.60--1.84)           \<0.0001
   Non-US-born                                                               88.9 (86.2--91.6)         1.58 (1.46--1.71)           \<0.0001
  **Speaks English well or very well**                                                                                             
   Mainland-US-born                                                          98.1 (97.0--99.2)         Ref.                        \-
   Puerto Rico-born                                                          53.2 (40.8--65.6)         0.54 (0.43--0.68)           \<0.0001
   Non-US-born                                                               64.2 (60.5--67.9)         0.65 (0.62--0.69)           \<0.0001
  **Received care at a Ryan White HIV/AIDS Program-funded facility ^b,c^**                                                         
   Mainland-US-born                                                          68.9 (64.5--73.4)         Ref.                        \--
   Puerto Rico-born                                                          91.0 (83.6--98.5)         1.30 (1.19--1.41)           \<0.0001
   Non-US-born                                                               77.8 (73.4--82.3)         1.11 (1.05--1.19)           0.0008
  **Had any Ryan White coverage ^d^**                                                                                              
   Mainland-US-born                                                          40.4 (36.2--44.7)         Ref.                        \-
   Puerto Rico-born                                                          43.7 (37.1--50.3)         1.06 (0.89--1.27)           0.5296
   Non-US-born                                                               62.9 (58.9--66.9)         1.57 (1.41--1.74)           \<0.0001
  **Binge drinking, past 30 days ^e^**                                                                                             
   Mainland-US-born                                                          21.9 (18.5--25.2)         Ref.                        \--
   Puerto Rico-born                                                          18.9 (8.7--29.2)          0.87 (0.49--1.52)           0.5886
   Non-US-born                                                               15.7 (13.2--18.3)         0.72 (0.58--0.90)           0.0041
  **Non-injection drug use**                                                                                                       
   Mainland-US-born                                                          37.4 (33.3--41.4)         Ref.                        \-
   Puerto Rico-born                                                          17.7 (14.7--20.7)         0.47 (0.39--0.58)           \<0.0001
   Non-US-born                                                               14.2 (11.6--16.7)         0.38 (0.31--0.47)           \<0.0001
  **Injection drug use**                                                                                                           
   Mainland-US-born                                                          4.3 (2.5--6.1)            Ref.                        \-
   Puerto Rico-born                                                          1.5 (0.7--2.3)            0.35 (0.18--0.70)           0.0066
   Non-US-born ^f^                                                           \-                        \-                          \-
  **Major or other depression, past 2 weeks ^g^**                                                                                  
   Mainland-US-born                                                          27.6 (24.0--31.2)         Ref.                        \-
   Puerto Rico-born                                                          22.2 (18.5--25.9)         0.80 (0.66--0.98)           0.0521
   Non-US-born                                                               16.9 (14.1--19.8)         0.61 (0.49--0.76)           \<0.0001
  **Moderate to severe anxiety, past 2 weeks ^h^**                                                                                 
   Mainland-US-born                                                          20.7 (17.5--24.0)         Ref.                        \-
   Puerto Rico-born                                                          19.1 (16.6--21.6)         0.92 (0.75--1.13)           0.4509
   Non-US-born                                                               11.2 (8.9--13.5)          0.54 (0.42--0.70)           \<0.0001
  **Stage 3 classification (AIDS)**                                                                                                
   Mainland-US-born                                                          50.6 (46.5--54.7)         Ref.                        \--
   Puerto Rico-born                                                          56.5 (52.2--60.8)         1.12 (1.00--1.24)           0.0352
   Non-US-born                                                               58.5 (54.8--62.1)         1.16 (1.04--1.28)           0.0056

Notes: CI, Confidence Interval; all percentages are weighted; time period is 12 months prior to interview unless otherwise noted; all measures are self-reported unless otherwise noted. ^a^ *p*-value compared with US-born. ^b^ Documented in medical record. ^c^ Any Parts A, B, C, D, or F funding. ^d^ Includes AIDS Drug Assistance Program (ADAP) and other RWHAP support. ^e^ Drinking ≥5 alcoholic beverages in a single sitting for men, and ≥4 for women. ^f^ Coefficient of variation \>0.3. Estimate is unstable. ^g^ Using the Patient Health Questionnaire Depression Scale (PHQ-8). ^h^ Using the Generalized Anxiety Disorder Scale (GAD-7).
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###### 

HIV outcomes among Hispanic/Latino adults with diagnosed HIV by place of birth, United States---Medical Monitoring Project, 2015--2018 (n = 2564).

                                                       Weighted Row % (95% CI)   Prevalence Ratio (95% CI)   *p*-Value ^a^
  ---------------------------------------------------- ------------------------- --------------------------- ---------------
  **ART prescription**                                                                                       
   Mainland-US-born                                    78.6 (74.5--82.6)         Ref.                        \-
   Puerto Rico-born                                    94.0 (91.8--96.2)         1.20 (1.13--1.26)           \<0.0001
   Non-US-born                                         90.9 (88.4--93.4)         1.16 (1.09--1.23)           \<0.0001
  **100% adherent to ART doses, past 30 days ^b,c^**                                                         
   Mainland-US-born                                    38.6 (34.5--42.7)         Ref.                        \-
   Puerto Rico-born                                    41.5 (36.2--46.9)         1.08 (0.91--1.27)           0.37
   Non-US-born                                         44.7 (41.0--48.3)         1.16 (1.01--1.33)           0.03
  **Retention in care ^d^**                                                                                  
   Mainland-US-born                                    77.3 (73.1--81.4)         Ref.                        \-
   Puerto Rico-born                                    94.3 (90.8--97.8)         1.22 (1.15--1.30)           \<0.0001
   Non-US-born                                         87.3 (84.5--90.1)         1.13 (1.06--1.20)           \<0.0001
  **Recent viral suppression ^e^**                                                                           
   Mainland-US-born                                    65.1 (60.8--69.4)         Ref.                        \-
   Puerto Rico-born                                    84.6 (80.8--88.5)         1.30 (1.20--1.40)           \<0.0001
   Non-US-born                                         80.1 (76.8--83.4)         1.23 (1.14--1.32)           \<0.0001
  **Sustained viral suppression ^f^**                                                                        
   Mainland-US-born                                    57.3 (53.1--61.5)         Ref.                        \-
   Puerto Rico-born                                    74.6 (70.5--78.8)         1.30 (1.19--1.42)           \<0.0001
   Non-US-born                                         73.8 (70.4--77.2)         1.29 (1.18--1.40)           \<0.0001

Notes: CI, Confidence Interval; all percentages are weighted; time period is 12 months prior to interview unless otherwise noted; all measures documented in medical record unless otherwise noted. ^a^ *p*-value compared with US-born. ^b^ Self-reported. ^c^ Among persons taking ART. ^d^ 2 visits at least 90 days apart in the past 12 months. ^e^ Most recent viral load that was undetectable or \<200 copies/mL. ^f^ All viral loads in the past 12 months undetectable or \<200 copies/mL.

ijerph-17-00171-t004_Table 4

###### 

HIV outcomes among Puerto Rico-born Hispanic/Latino adults with diagnosed HIV by current residency, United States---Medical Monitoring Project, 2015--2018 (n = 634).

  Characteristics                                    Reside in PR (n = 435)   Reside in Mainland US (n = 199)   *p*-Value                       
  -------------------------------------------------- ------------------------ --------------------------------- ----------- ------------------- ----------
  **ART prescription**                               419                      95.5 (94.8--96.2)                 184         91.0 (85.5--96.4)   0.0066
  **100% adherent to ART doses, past 30 days ^a^**   170                      42.4 (35.8--49.0)                 78          39.7 (31.9--47.5)   0.5902
  **Retention in care ^b^**                          424                      97.2 (95.2--99.1)                 178         88.4 (82.1--94.7)   0.0192
  **Recent viral suppression ^c^**                   381                      87.9 (85.1--90.6)                 158         78.1 (71.0--85.2)   \<0.0001
  **Sustained viral suppression ^d^**                335                      78.2 (75.4--80.9)                 136         67.6 (60.1--75.0)   \<0.0001

Notes: CI, Confidence Interval; all percentages are weighted; time period is 12 months prior to interview unless otherwise noted; all measures documented in medical record unless otherwise noted. ^a^ Among persons taking ART. ^b^ 2 visits at least 90 days apart in the past 12 months. ^c^ Most recent viral load that was undetectable or \<200 copies/mL. ^d^ All viral loads in the past 12 months undetectable or \<200 copies/mL.
